Clinical trial
A Phase II, Single-center, Randomized Double Blind, Placebo Controlled Study to Evaluate the Effect of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Ambulant Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)
NCT07414212 is registered in ClinicalTrials.gov with Biogipuzkoa Health Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Single-center, Randomized Double Blind, Placebo Controlled Study to Evaluate the Effect of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Ambulant Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Biogipuzkoa Health Research Institute
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 25, 2025
- Completion date
- November 25, 2027
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.